R Squared’s Cadrenal Therapeutics CVKD Stock Holding History

R Squared’s Portfolio CVKD Stock Details CVKD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-40	Closed	-$580	–	591
2024 Q4	$580	Buy	+40	New	+$578	﹤0.01%	1533

Other funds holding CVKD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

PWA

Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return

AIC

Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return

R Squared's CVKD Position: Q1 2025 in Review

R Squared sold out of Cadrenal Therapeutics (CVKD) in Q1 2025, closing a stake of 40 shares — an estimated $580 sold.

R Squared first reported a position in CVKD in Q4 2024 and held it in 1 quarter. The position peaked at $580 in Q4 2024. 16 funds tracked by Wall St. Rank hold CVKD as of Q1 2025.

R Squared reported no remaining Cadrenal Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 40 Cadrenal Therapeutics shares in Q1 2025, an estimated $580.
R Squared first reported a position in Cadrenal Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Cadrenal Therapeutics position peaked at $580 in Q4 2024.
16 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.